Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

For the first time, starting July 1, people in the US will be able to access GLP-1 drugs for weight loss through a new pilot program offered by the federal health insurance program Medicare.

Until now, Medicare covered GLP-1 medications such as Ozempic only for certain conditions like diabetes, but not for weight loss.

The new 18-month Medicare GLP-1 Bridge Program, which will run till the end of 2027, aims to make these high-cost weight-loss medications more accessible to eligible beneficiaries.

According to a KFF analysis of 2023 Part D enrollment data, an estimated 3.8 million Medicare beneficiaries could qualify for the program.

More than 70 per cent of adults in the United States are considered to have obesity or screen as overweight. Studies have proven that GLP-1s are an effective tool in weight reduction, as well as improving other markers of good health, such as blood pressure, lipid profiles, and blood sugar levels.

What Drugs Will Be Covered?

Eligible beneficiaries will be able to access the following GLP-1 weight-loss medications:

• Novo Nordisk's Wegovy injections and tablets
• Eli Lilly's Foundayo tablets
• Eli Lilly's Zepbound KwikPen

The medications will be covered only when prescribed for weight management and when beneficiaries meet the program's medical eligibility criteria.

Who Will Be Eligible?

The program is available only to certain members of Medicare Part D prescription drug plans who want to lose excess weight and maintain weight loss.

Although the program operates outside standard Medicare Part D coverage, beneficiaries can participate only if they are enrolled in:

• An eligible stand-alone Medicare Part D prescription drug plan under Original Medicare, or
• An eligible Medicare Advantage plan that includes prescription drug coverage.

People enrolled in certain less common Medicare plans, including the Program of All-inclusive Care for the Elderly (PACE), may also qualify if they also have a stand-alone Part D plan, Washington Post reported.

According to the Centers for Medicare & Medicaid Services (CMS), most of Medicare's approximately 57 million Part D enrollees are in eligible plans.

However, coverage is not automatic. Providers and pharmacists will identify eligible patients, submit the required forms and obtain prior authorization before treatment can begin. Claims, prior authorization requests and pharmacy payments will be handled by Humana, while Part D plans will not be involved in the process.

How Much Will It Cost?

Eligible beneficiaries will pay a $50 monthly copay for the covered medications.

However, because the program operates outside Medicare Part D coverage:

• The $50 copay will not count toward a beneficiary's Part D deductible.
• It also will not count toward the 2026 Part D annual out-of-pocket spending cap of $2,100.
• The copay is not eligible for the Medicare Prescription Payment Plan, which allows beneficiaries to spread prescription drug costs throughout the year.

What Happens After 2027?

The pilot program is temporary and is scheduled to end in December 2027, unless it is extended.

"It's certainly good news for Medicare beneficiaries who have been essentially shut out of the market for GLP-1s for weight loss if they wanted to use insurance coverage. However, it is a temporary program. It is not a permanent change in Medicare coverage," said Juliette Cubanski, Vice President and Director of Medicare Policy at KFF.

If the program is not extended, beneficiaries who rely on the medications may have to pay higher out-of-pocket prices or discontinue treatment beginning in January 2028, which experts said could lead to weight regain based on current GLP-1 therapies, the Post reported.

A recent study has found that a modified form of vitamin B12 therapy may prove to be a new and promising way to treat glioblastoma, one of the most aggressive forms of brain cancer.

With limited treatment options, patients are usually treated with surgery, radiation therapy, and chemotherapy. Usually, the chance of survival is not bright after diagnosis.

New Vitamin B-12 Compound Shows Promise In Glioblastoma Treatment

Published in the journal Oncoscience, the research study is based on nitrosylcobalamin (NO-Cbl), a vitamin B12-based compound that contains and slowly releases nitric oxide.

The main purpose of the study was to find out whether the vitamin B-12 compound could cross the blood-brain barrier, a protective layer that prevents many medicines from reaching the brain and directly targeting glioblastoma tumors.

The blood-brain barrier is one of the biggest challenges in treating glioblastoma, as it protects the brain from harmful substances, blocking many cancer drugs from reaching tumor tissue.

Also read: Ebola Outbreak Spreads To Fourth Province In DR Congo As Cases Rise To 1,274

About The Study

The researchers examined how NO-Cbl affected different types of cancer cells, particularly how it moved through the body of rats with glioblastoma. The results showed that NO-Cbl had an anti-cancer effect on several types of tumors.

Most importantly, the compound was able to cross the blood-brain barrier and accumulate inside glioblastoma tumors in animal studies.

Researchers also found that the compound remained active in tumor tissue for at least 24 hours, delivering nitric oxide directly to cancer cells without affecting normal tissues.

They also tested NO-Cbl in combination with two existing glioblastoma treatments: temozolomide, the standard chemotherapy drug for the disease, and TRAIL, an experimental cancer therapy.

In laboratory-grown glioblastoma cells, the combinations alleviated cancer cell growth much more effectively than any of the treatments used on their own.

Also read: Cholera Outbreak In Sudan: 117 Dead, 838 Suspected Cases, Says WHO

About Glioblastoma

A glioblastoma is a fast-growing glioma, a type of tumor that stems from glial cells, which protect nerve cells in the brain and spinal cord.

Glioblastoma can occur at any age but is more commonly found in older adults. The average age at diagnosis is 64.

Public figures among those afflicted include former President Joe Biden's son, Beau Biden, who succumbed to this cancer in 2015. John McCain also passed away in 2018 due to glioblastoma.

According to the MD Anderson Cancer Center, around 12,000 glioblastoma cases are diagnosed in the United States every year. All glioblastomas are grade IV brain tumors, meaning they contain the most abnormal looking cells and are the most aggressive.

About 13,000 Americans are diagnosed with glioblastoma each year, accounting for almost half of all cancerous brain tumors, according to the Cleveland Clinic. More than 10,000 people in the U.S. will succumb to the disease every year, the National Brain Tumor Society reports.

In the light of limited treatment options for glioblastoma, this study is a ray of hope as it shows promise in slowing down the growth of cancer cells by overcoming challenges like treatment resistance.

Heart failure (HF) remains a major global health challenge, affecting more than 64 million adults worldwide.

To improve how the condition is prevented, diagnosed and managed, leading cardiovascular organizations, including the American Heart Association (AHA) and the American College of Cardiology (ACC), have released the "Second Universal Definition of Heart Failure."

The updated definition addresses changes in disease manifestations, diagnostic strategies and the understanding of heart failure's underlying biology. It also aims to establish a unified framework for clinicians, researchers, health systems and policymakers worldwide.

Published on behalf of the ACC, AHA, European Society of Cardiology (ESC) and World Heart Federation (WHF), in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the ESC and the Japanese Heart Failure Society (JHFS), the document updates the First Universal Definition of Heart Failure, released in 2021. It has been published simultaneously in Circulation, Journal of the American College of Cardiology (JACC), European Heart Journal and Global Heart.

What Does The Updated Definition Include?

The prevalence of heart failure continues to rise due to ageing populations and increasing rates of obesity, Type 2 diabetes and high blood pressure.

To better address this growing burden, the new framework introduces several important changes.

• Universal classification of heart failure causes:

• Moving beyond rigid ejection fraction cut-offs:

• Greater emphasis on early detection:

• Recognition that heart failure is dynamic:

• Attention to social and global factors:

Why The New Definition Matters

The revised definition provides a common framework for clinicians, researchers, health systems and policymakers worldwide, helping standardize diagnosis, strengthen research and support more personalized care.

The consensus document will also serve as the foundation for the upcoming American Heart Association/American College of Cardiology Heart Failure Guideline, expected to be published in late 2027.

"Heart failure remains a major challenge that continues to grow globally, and inconsistencies in how it is defined have limited progress in research and treatment. This updated definition provides a clearer, more consistent framework to help clinicians identify risk earlier and guide more personalized treatment approaches that can help improve patient outcomes worldwide," said Mary Norine Walsh, co-chair of the consensus document.

"The new framework recognizes that heart failure is not a static condition. By focusing on stages of disease, underlying causes and disease trajectories—including improvement, remission and recovery—we can better tailor care and advance prevention efforts," she added.